Ceribell, a medical tech company specializing in neurological diagnostics, reported a 30% revenue increase to $29.3 million in Q3 2026, driven by strong growth in existing accounts and new customer additions. The company launched its delirium monitoring solution and received FDA clearance for new EEG analysis tools, positioning it for growth in 2027. Despite a net loss of $21.4 million, Ceribell raised its full-year 2026 revenue forecast to $115-$117 million, reflecting confidence in its core business expansion and product innovation.
Ceribell's third quarter 2026 financial results provide context for healthcare sector performance. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 92 rose and 55 fell today. Notable movers include WGS (GeneDx Holdings Corp) at USD 68.89 with a 1-day change of +7.49% and Pluang order activity showing 66% Sell / 34% Buy, SMMT (Summit Therapeutics Inc) at USD 15.86 with a 1-day change of +7.09% and 0% Sell / 100% Buy order activity, and TNGX (Tango Therapeutics Inc.) at USD 23.17 with a 1-day change of +6.48%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
